A New Approach to Rare Disease Drug Development: Targeting Shared Biological Mechanisms
Dr. Anna Greka, a Harvard professor and physician at Mass General Brigham, is pioneering an approach called 'nodal biology' that identifies shared biological mechanisms across different rare diseases. This strategy aims to develop single drugs capable of treating multiple conditions, thereby increasing the potential patient population and making drug development more economically viable for investors. Greka's Ladders to Cures Accelerator initiative seeks to accelerate treatment discovery by focusing on these overlapping disease pathways. Her research has already demonstrated success in identifying a mechanism relevant to rare kidney diseases as well as those affecting the eye and brain. The approach could attract greater investment into an area traditionally seen as high-risk due to small patient populations. The Broad Institute will host the 3rd Annual Ladders to Cures Symposium on October 27, where Greka and her colleagues plan to discuss further advancements in this field.
Topics: biotechnology drug development model nodal biology rare disease research